MetaVia Inc. (Nasdaq: MTVA) released an investor presentation outlining its clinical-stage pipeline focused on obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company highlighted DA-1726, a once-weekly injectable GLP-1 receptor/glucagon receptor dual agonist, reporting Phase 1 data at 48 mg showing 9.1% body weight loss by Day 54, a 3.8-inch waist reduction, a 0.22 decrease in HbA1c, and a 23.7% reduction in liver stiffness (VCTE), with mostly mild to moderate side effects. MetaVia said it plans additional Phase 1 dose-titration work up to 64 mg, with data expected by year-end 2026, and noted a 16-week study in obese patients with type 2 diabetes targeted for first patient in during the first half of 2026. The presentation also covered vanoglipel (DA-1241), an oral GPR119 agonist, citing Phase 2a results in presumed MASH that met the primary endpoint, including an ALT reduction of 22.8 U/L over 16 weeks, improvements in inflammation and fibrosis markers, significant HbA1c reductions at 100 mg versus placebo at Week 16, and no treatment-related discontinuations. The company indicated it plans to present additional exploratory endpoints, including MRI-PDFF, at major medical conferences and is seeking a combination or licensing partner. You can access the full presentation through the link below. https://www.metaviatx.com

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.